Plasma plasminogen activator inhibitor type 1 (PAI-1) antigen and activity in patients at baseline and during placebo and pravastatin treatment and in matched controls
| Patients | |||||
|---|---|---|---|---|---|
| Substance P dose (pmol/min) | Controls | Baseline | Placebo | Pravastatin | |
| Data are mean (SEM). | |||||
| PAI-1 antigen (ng/ml) | |||||
| Infused arm | 0 | 23 (9) | 40 (10) | 47 (12) | 48 (15) |
| 2 | 24 (8) | 43 (10) | 47 (11) | 44 (13) | |
| 4 | 24 (8) | 41 (9) | 46 (11) | 51 (16) | |
| 8 | 29 (10) | 39 (9) | 46 (12) | 46 (14) | |
| Non-infused arm | 0 | 22 (8) | 44 (11) | 50 (13) | 50 (16) |
| 2 | 23 (8) | 40 (9) | 51 (12) | 51 (18) | |
| 4 | 26 (9) | 39 (9) | 51 (14) | 46 (14) | |
| 8 | 28 (8) | 38 (9) | 48 (11) | 46 (14) | |
| PAI-1 activity (AU/ml) | |||||
| Infused arm | 0 | 9 (3) | 13 (2) | 15 (3) | 13 (3) |
| 2 | 10 (4) | 10 (2) | 16 (3) | 13 (2) | |
| 4 | 9 (4) | 9 (3) | 13 (3) | 14 (2) | |
| 8 | 11 (5) | 11 (3) | 13 (3) | 13 (2) | |
| Non-infused arm | 0 | 12 (3) | 14 (3) | 14 (3) | 15 (3) |
| 2 | 8 (4) | 13 (2) | 16 (3) | 13 (2) | |
| 4 | 11 (5) | 10 (3) | 14 (2) | 13 (3) | |
| 8 | 9 (4) | 12 (3) | 13 (3) | 12 (3) | |